Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE: 688062)
Health Care · Biotechnology · CN
CN¥24.78
-8.36% today · -44.1% 1Y
Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE: 688062) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.60B and employs 1,356 people.
Over the last twelve months the share price has lost 44.1%, trading between 23.50 and 48.48.
Tweenvest scores Mabwell (Shanghai) Bioscience Co., Ltd. across four factors: quality 32/100, value 70/100, growth 100/100. Its strongest factor is growth.
688062 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.60B
- Revenue (TTM)
- $128.66M
- P/E
- —
- EPS
- -2.31
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- CN¥48.48
- 52-week low
- CN¥23.50
- Avg volume (3M)
- —
- Shares outstanding
- 445.54M
- Employees
- 1,356
- Next earnings
- —
About Mabwell (Shanghai) Bioscience Co., Ltd.
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
- ISIN
- CNE100005RD2
- Founded
- 2017
- Listed since
- Jan 18, 2022
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PYC Therapeutics LimitedASX: PYC | $1.68B | AU$2.45 | -0.41% |
| Novoprotein Scientific Inc.SHSE: 688137 | $1.67B | CN¥161.18 | +0.49% |
| COMPASS Pathways plcNasdaqGS: CMPS | $1.66B | $11.59 | -3.46% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.60B | $24.40 | -1.37% |
| uniQure N.V.NasdaqGS: QURE | $1.57B | $21.52 | -4.74% |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | $1.52B | $15.28 | -1.29% |
| Shanghai OPM Biosciences Co., Ltd.SHSE: 688293 | $1.52B | CN¥71.50 | -10.19% |
| Syndax Pharmaceuticals, Inc.NasdaqGS: SNDX | $1.52B | $16.49 | -2.97% |
Figures last refreshed Oct 11, 2026.